At SMS-oncology we believe that true passion and devotion are key to be able to exceed in what you do. Being committed and dedicated to oncology, we support our clients with our knowledgeable experts and devoted clinical project teams in a joint effort to reaching the goals and milestones. We take pride in contributing to the successful oncology drug development of our sponsors.
SMS-oncology is a full-service Contract Research Organization (CRO) dedicated to the conduct of clinical oncology studies in Europe, with particular expertise in early phase and immuno-oncology studies. We provide the complete range of clinical trial services, from start-up to completion, from Phase I to IV. In addition, we provide strategic oncology drug development consulting and expert advice as we understand the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market.
Our unique competence and value proposition of integrating consultancy and clinical operations is captured in our 4D service: providing direction to our sponsors along the entire drug-data-dossier path. SMS-oncology sets itself apart from typical CROs by our in-depth oncology drug development expertise, providing strategic support and turning complex data into meaningful insights to navigate the best way forward. Our proactive guidance from the design of oncology studies to the full execution gives our sponsors not only a head start, but also allows our clients to be on top of the data, make informed decisions, mitigate risks and identify opportunities during study conduct. This gives our sponsors’ oncology compounds the highest chance of success.
Located directly next to Amsterdam Airport Schiphol and with teams of dedicated oncology professionals and close involvement from the senior management team, SMS-oncology ensures our sponsors’ clinical studies are executed on time, on budget, and in compliance with regulatory and industry standards.
We focus on building long-term relationships with our sponsors. The majority of our clients include emerging small to midsize biotech companies, while also serving several large pharmaceutical corporations as well as individual investigators and research groups. We take pride in offering a flexible and tailor-made approach to the specific needs of every project, either by providing our full-service solution or stand-alone oncology services.
We thrive on engaging partnerships: assertive, innovative and thinking along with our sponsors. Our client satisfaction results are the reflection of this:
French research tax credit (CIR)
SMS-oncology has been notified of the renewal of its French research tax credit (crédit d’impôt recherche - CIR) accreditation for another three years, until the end of 2020, by the competent authority (Ministère de lʼEnseignement supérieur, de la Recherche et de lʼInnovation). The accreditation gives French companies the ability to claim tax relief of 30% on their clinical studies related costs that are contracted to SMS-oncology.